Treatment options for methicillin-resistant Staphylococcus aureus (MRSA) infection: Where are we now?

Journal of Global Antimicrobial Resistance

Volumn 2, Issue 3, 2014, Pages 133-140

  Edwards, B ^a   Andini, R ^b   Esposito, S ^c   Grossi, P ^d   Lew, D ^e   Mazzei, T ^f   Novelli, A ^f   Soriano, A ^g   Gould, I M ^h  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY OF SALERNO   (Italy)

^d UNIVERSITY OF INSUBRIA   (Italy)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f UNIVERSITY OF FLORENCE   (Italy)

^g HOSPITAL CLÍNIC   (Spain)

^h ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

MRSA; Susceptibility testing; Treatment

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFTAROLINE; COTRIMOXAZOLE; DAPTOMYCIN; FOSFOMYCIN; LINEZOLID; OXACILLIN; OXAZOLIDINONE DERIVATIVE; RIFAMPICIN; TEDIZOLID; VANCOMYCIN;

AREA UNDER THE CURVE; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

EID: 84906790946     PISSN: 22137165     EISSN: 22137173     Source Type: Journal    
DOI: 10.1016/j.jgar.2014.03.009     Document Type: Review

References (124)

1. A.M. Bal, J. Garau, I.M. Gould, C.H. Liao, T. Mazzei, and G.R. Nimmo et al. Vancomycin in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection: end of an era? J Glob Antimicrob Resist 1 2013 24 28
2. I.M. Gould Is vancomycin redundant for serious staphylococcal infection? Int J Antimicrob Agents 36 Suppl. 2 2010 S55 S57
3. S.J. van Hal, and V.G. Fowler Jr. Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections? Clin Infect Dis 56 2013 1779 1788
4. N.E. Holmes, P.D. Johnson, and B.P. Howden Relationship between vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infections J Clin Microbiol 50 2012 2548 2552
5. R. Kullar, S.L. Davis, D.P. Levine, and M.J. Rybak Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets Clin Infect Dis 52 2011 975 981
6. A. Soriano, F. Marco, J.A. Martínez, E. Pisos, M. Almela, and V.P. Dimova et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia Clin Infect Dis 46 2008 193 200
7. J.F. Mohr, B.E. Murray, and 1. Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus Clin Infect Dis 44 2007 1536 1542
8. M.J. Rybak, C. Vidaillac, H.S. Sader, P.R. Rhomberg, H. Salimnia, and L.E. Briski et al. Evaluation of vancomycin susceptibility testing for methicillin-resistant Staphylococcus aureus: comparison of Etest and three automated testing methods J Clin Microbiol 51 2013 2077 2081
9. S.J. van Hal, T. Barbagiannakos, M. Jones, M.C. Wehrhahn, J. Mercer, and D. Chen et al. Methicillin-resistant Staphylococcus aureus vancomycin susceptibility testing: methodology correlations, temporal trends and clonal patterns J Antimicrob Chemother 66 2011 2284 2287
10. C. Liu, A. Bayer, S.E. Cosgrove, R.S. Daum, S.K. Fridkin, and R.J. Gorwitz et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary Clin Infect Dis 52 2011 285 292
11. C. Liu, A. Bayer, S.E. Cosgrove, R.S. Daum, S.K. Fridkin, and R.J. Gorwitz et al. Infectious Diseases Society of America Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children Clin Infect Dis 52 2011 e18 e55
12. S.J. van Hal, T.P. Lodise, and D.L. Paterson The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis Clin Infect Dis 54 2012 755 771
13. M.N. Mavros, G.S. Tansarli, K.Z. Vardakas, P.I. Rafailidis, D.E. Karageorgopoulos, and M.E. Falagas Impact of vancomycin minimum inhibitory concentration on clinical outcomes of patients with vancomycin-susceptible Staphylococcus aureus infections: a meta-analysis and meta-regression Int J Antimicrob Agents 40 2012 496 509
14. J.T. Jacob, and C.A. DiazGranados High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis Int J Infect Dis 17 2013 e93 e100
15. C.L. Moore, P. Osaki-Kiyan, N.Z. Haque, M.B. Perri, S. Donabedian, and M.J. Zervos Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study Clin Infect Dis 54 2012 51 58
16. K.P. Murray, J.J. Zhao, S.L. Davis, R. Kullar, K.S. Kaye, and P. Lephart et al. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study Clin Infect Dis 56 2013 1562 1569
17. C.W. Cheng, P.C. Hsu, C.C. Yang, H.J. Chang, L.K. Siu, and T.L. Wu et al. Influence of early daptomycin therapy on treatment outcome of methicillin-resistant Staphylococcus aureus bacteraemia with high vancomycin minimum inhibitory concentrations Int J Antimicrob Agents 41 2013 293 294
18. J. Price, S. Atkinson, M. Llewelyn, and J. Paul Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin Clin Infect Dis 48 2009 997 998
19. C.J. Walraven, M.S. North, L. Marr-Lyon, P. Deming, G. Sakoulas, and R.C. Mercier Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia J Antimicrob Chemother 66 2011 2386 2392
20. L. Rojas, E. Bunsow, P. Muñoz, E. Cercenado, M. Rodríguez-Créixems, and E. Bouza Vancomycin MICs do not predict the outcome of methicillin-resistant Staphylococcus aureus bloodstream infections in correctly treated patients J Antimicrob Chemother 67 2012 1760 1768
21. R. Hope, R.M. Blackburn, N.Q. Verlander, A.P. Johnson, A. Kearns, and R. Hill et al. UK Clinical Infection Research Group Vancomycin MIC as a predictor of outcome in MRSA bacteraemia in the UK context J Antimicrob Chemother 68 2013 2641 2647
22. M.J. Rybak, B.M. Lomaestro, J.C. Rotschafer, R.C. Moellering, W.A. Craig, and M. Billeter et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists Clin Infect Dis 49 2009 325 327
23. N. Patel, M.P. Pai, K.A. Rodvold, B. Lomaestro, G.L. Drusano, and T.P. Lodise Vancomycin: we can't get there from here Clin Infect Dis 52 2011 969 974
24. D.I. Hsu, L.K. Hidayat, R. Quist, J. Hindler, A. Karlsson, and A. Yusof et al. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of methicillin-resistant Staphylococcus aureus (MRSA) infections Int J Antimicrob Agents 32 2008 378 385
25. S.J. van Hal, and D.L. Paterson Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates Antimicrob Agents Chemother 55 2011 405 410
26. C.M. Bland, W.H. Porr, K.A. Davis, and K.B. Mansell Vancomycin MIC susceptibility testing of methicillin-susceptible and methicillin-resistant Staphylococcus aureus isolates: a comparison between Etest® and an automated testing method South Med J 103 2010 1124 1128
27. S.J. van Hal, M. Jones, I.B. Gosbell, and D.L. Paterson Vancomycin heteroresistance is associated with reduced mortality in ST239 methicillin-resistant Staphylococcus aureus blood stream infections PLoS ONE 6 2011 e21217
28. S.J. van Hal, D.L. Paterson, and T.P. Lodise Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter Antimicrob Agents Chemother 57 2013 734 744
29. K.H. Park, E.S. Kim, H.S. Kim, S.J. Park, K.M. Bang, and H.J. Park et al. Comparison of the clinical features, bacterial genotypes and outcomes of patients with bacteraemia due to heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-susceptible S. aureus J Antimicrob Chemother 67 2012 1843 1849
30. A.M. Casapao, S.N. Leonard, S.L. Davis, T.P. Lodise, N. Patel, and D.A. Goff et al. Clinical outcomes in patients with heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) bloodstream infection Antimicrob Agents Chemother June 2013 [Epub ahead of print]
31. I. Uçkay, L. Bernard, M. Buzzi, S. Harbarth, P. François, and E. Huggler et al. High prevalence of isolates with reduced glycopeptide susceptibility in persistent or recurrent bloodstream infections due to methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 56 2012 1258 1264
32. H.J. Chang, P.C. Hsu, C.C. Yang, L.K. Siu, A.J. Kuo, and J.H. Chia et al. Influence of teicoplanin MICs on treatment outcomes among patients with teicoplanin-treated methicillin-resistant Staphylococcus aureus bacteraemia: a hospital-based retrospective study J Antimicrob Chemother 67 2012 736 741
33. K.Y. Chen, H.J. Chang, P.C. Hsu, C.C. Yang, J.H. Chia, and T.L. Wu et al. Relationship of teicoplanin MICs to treatment failure in teicoplanin-treated patients with methicillin-resistant Staphylococcus aureus pneumonia J Microbiol Immunol Infect 46 2013 210 216
34. S.S. Richter, S.W. Satola, E.K. Crispell, K.P. Heilmann, C.L. Dohrn, and F. Riahi et al. Detection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United States J Clin Microbiol 49 2011 4203 4207
35. S.W. Satola, M.M. Farley, K.F. Anderson, and J.B. Patel Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method J Clin Microbiol 49 2011 177 183
36. P. Vaudaux, E. Huggler, L. Bernard, T. Ferry, A. Renzoni, and D.P. Lew Underestimation of vancomycin and teicoplanin MICs by broth microdilution leads to underdetection of glycopeptide-intermediate isolates of Staphylococcus aureus Antimicrob Agents Chemother 54 2010 3861 3870
37. J.M. Swenson, K.F. Anderson, D.R. Lonsway, A. Thompson, S.K. McAllister, and B.M. Limbago et al. Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin-intermediate Staphylococcus aureus J Clin Microbiol 47 2009 2013 2017
38. H.S. Sader, R.N. Jones, K.L. Rossi, and M.J. Rybak Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals J Antimicrob Chemother 64 2009 1024 1028
39. B.P. Howden, J.K. Davies, P.D. Johnson, T.P. Stinear, and M.L. Grayson Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications Clin Microbiol Rev 23 2010 99 139
40. P. Moreillon, A. Bizzini, M. Giddey, J. Vouillamoz, and J.M. Entenza Vancomycin-intermediate Staphylococcus aureus selected during vancomycin therapy of experimental endocarditis are not detected by culture-based diagnostic procedures and persist after treatment arrest J Antimicrob Chemother 67 2012 652 660
41. B.P. Howden, A.Y. Peleg, and T.P. Stinear The evolution of vancomycin intermediate Staphylococcus aureus (VISA) and heterogenous-VISA Infect Genet Evol 21 2014 575 582
42. M.M. Mwangi, S.W. Wu, Y. Zhou, K. Sieradzki, H. de Lencastre, and P. Richardson et al. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing Proc Natl Acad Sci U S A 104 2007 9451 9456
43. Y. Harigaya, D. Ngo, A.J. Lesse, V. Huang, and B.T. Tsuji Characterization of heterogeneous vancomycin-intermediate resistance MIC and accessory gene regulator (agr) dysfunction among clinical bloodstream isolates of Staphylococcus aureus BMC Infect Dis 11 2011 287
44. C. Hafer, Y. Lin, J. Kornblum, F.D. Lowy, and A.C. Uhlemann Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus Antimicrob Agents Chemother 56 2012 5845 5851
45. T. Takata, M. Miyazaki, M. Futo, S. Hara, S. Shiotsuka, and H. Kamimura et al. Presence of both heterogeneous vancomycin-intermediate resistance and β-lactam antibiotic-induced vancomycin resistance phenotypes is associated with the outcome in methicillin-resistant Staphylococcus aureus bloodstream infection Scand J Infect Dis 45 2013 203 212
46. P.A. Moise-Broder, A. Forrest, M.C. Birmingham, and J.J. Schentag Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections Clin Pharmacokinet 43 2004 925 942
47. S. Zelenitsky, E. Rubinstein, R. Ariano, H. Iacovides, P. Dodek, and Y. Mirzanejad et al. Cooperative Antimicrobial Therapy of Septic Shock - CATSS Database Research Group Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock Int J Antimicrob Agents 41 2013 255 260
48. M.S. Albur, K. Bowker, I. Weir, and A. MacGowan Factors influencing the clinical outcome of methicillin-resistant Staphylococcus aureus bacteraemia Eur J Clin Microbiol Infect Dis 31 2012 295 301
49. B.O. Claus, E.A. Hoste, K. Colpaert, H. Robays, J. Decruyenaere, and J.J. De Waele Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy J Crit Care 28 2013 695 700
50. E. Ocampos-Martinez, L. Penaccini, S. Scolletta, A. Abdelhadii, A. Devigili, and S. Cianferoni et al. Determinants of early inadequate vancomycin concentrations during continuous infusion in septic patients Int J Antimicrob Agents 39 2012 332 337
51. N. Petejova, A. Martinek, J. Zahalkova, J. Duricova, H. Brozmannova, and K. Urbanek et al. Vancomycin pharmacokinetics during high-volume continuous venovenous hemofiltration in critically ill septic patients Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 158 2014 65 72
52. E.N. Frazee, P.J. Kuper, G.E. Schramm, S.L. Larson, K.B. Kashani, and D.R. Osmon et al. Effect of continuous venovenous hemofiltration dose on achievement of adequate vancomycin trough concentrations Antimicrob Agents Chemother 56 2012 6181 6185
53. P. Martinez-Olondris, M. Rigol, D. Soy, L. Guerrero, C. Agusti, and M.A. Quera et al. Efficacy of linezolid compared to vancomycin in an experimental model of pneumonia induced by methicillin-resistant Staphylococcus aureus in ventilated pigs Crit Care Med 40 2012 162 168
54. J. Rello, J. Sole-Violan, M. Sa-Borges, J. Garnacho-Montero, E. Muñoz, and G. Sirgo et al. Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides Crit Care Med 33 2005 1983 1987
55. A.J. Verrall, R. Llorin, V.H. Tam, D.C. Lye, Z. Sulaiman, and L. Zhong et al. Efficacy of continuous infusion of vancomycin for the outpatient treatment of methicillin-resistant Staphylococcus aureus infections J Antimicrob Chemother 67 2012 2970 2973
56. M. Wysocki, F. Delatour, F. Faurisson, A. Rauss, Y. Pean, and B. Misset et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study Antimicrob Agents Chemother 45 2001 2460 2467
57. M.A. Cataldo, E. Tacconelli, E. Grilli, F. Pea, and N. Petrosillo Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis J Antimicrob Chemother 67 2012 17 24
58. S. Cianferoni, A. Devigili, E. Ocampos-Martinez, L. Penaccini, S. Scolletta, and A. Abdelhadii et al. Development of acute kidney injury during continuous infusion of vancomycin in septic patients Infection 41 2013 811 820
59. P.N. Panday, and M. Sturkenboom Continuous infusion of vancomycin less effective and safe than intermittent infusion, based on pharmacodynamic and pharmacokinetic principles Clin Infect Dis 49 2009 1964 1965
60. J.M. Entenza, T.R. Veloso, J. Vouillamoz, M. Giddey, and P. Moreillon Failure of vancomycin continuous infusion against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus Antimicrob Agents Chemother 55 2011 385 387
61. T.P. Lodise, G.L. Drusano, J.M. Butterfield, J. Scoville, M. Gotfried, and K.A. Rodvold Penetration of vancomycin into epithelial lining fluid in healthy volunteers Antimicrob Agents Chemother 55 2011 5507 5511
62. K. Skhirtladze, D. Hutschala, T. Fleck, F. Thalhammer, M. Ehrlich, and T. Vukovich et al. Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery Antimicrob Agents Chemother 50 2006 1372 1375
63. T.M. Duane, J.A. Weigelt, L.A. Puzniak, and D.B. Huang Linezolid and vancomycin in treatment of lower-extremity complicated skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus in patients with and without vascular disease Surg Infect (Larchmt) 13 2012 147 153
64. A. Horey, K.A. Mergenhagen, and A. Mattappallil The relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran's population: a retrospective analysis Ann Pharmacother 46 2012 1477 1483
65. World Health Organization WHO Expert Committee on specifications for pharmaceutical preparations 2006 WHO Geneva, Switzerland 347 390 Technical Report Series No. 937 Annex 7
66. O. Vesga, M. Agudelo, B.E. Salazar, C.A. Rodriguez, and A.F. Zuluaga Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator Antimicrob Agents Chemother 54 2010 3271 3279
67. P. Tattevin, A. Saleh-Mghir, B. Davido, I. Ghout, L. Massias, and C. Garcia de la Maria et al. Comparison of six generic vancomycin products for treatment of methicillin-resistant Staphylococcus aureus experimental endocarditis in rabbits Antimicrob Agents Chemother 57 2013 1157 1162
68. A.A. Bhalodi, P.K. Papasavas, D.S. Tishler, D.P. Nicolau, and J.L. Kuti Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults Antimicrob Agents Chemother 57 2013 1144 1149
69. Y. Tsuji, Y. Hiraki, K. Matsumoto, A. Mizoguchi, S. Sadoh, and T. Kobayashi et al. Evaluation of the pharmacokinetics of linezolid in an obese Japanese patient Scand J Infect Dis 44 2012 626 629
70. K.M. Muzevich, and K.B. Lee Subtherapeutic linezolid concentrations in a patient with morbid obesity and methicillin-resistant Staphylococcus aureus pneumonia: case report and review of the literature Ann Pharmacother 47 2013 e25
71. M.S. Dryden Linezolid pharmacokinetics and pharmacodynamics in clinical treatment J Antimicrob Chemother 66 Suppl. 4 2011 iv7 iv15
72. L. Morata, M. Cuesta, J.F. Rojas, S. Rodriguez, M. Brunet, and G. Casals et al. Risk factors for a low linezolid trough plasma concentration in acute infections Antimicrob Agents Chemother 57 2013 1913 1917
73. C. Adembri, S. Fallani, M.I. Cassetta, S. Arrigucci, A. Ottaviano, and P. Pecile et al. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion Int J Antimicrob Agents 31 2008 122 129
74. E. Boselli, D. Breilh, A. Caillault-Sergent, S. Djabarouti, C. Guillaume, and F. Xuereb et al. Alveolar diffusion and pharmacokinetics of linezolid administered in continuous infusion to critically ill patients with ventilator-associated pneumonia J Antimicrob Chemother 67 2012 1207 1210
75. F.G. De Rosa, S. Corcione, L. Baietto, A. Ariaudo, G. Di Perri, and V.M. Ranieri et al. Pharmacokinetics of linezolid during extracorporeal membrane oxygenation Int J Antimicrob Agents 41 2013 590 591
76. K. Gandelman, T. Zhu, O.A. Fahmi, P. Glue, K. Lian, and R.S. Obach et al. Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism J Clin Pharmacol 51 2011 229 236
77. H. Egle, R. Trittler, K. Kümmerer, and S.W. Lemmen Linezolid and rifampin: drug interaction contrary to expectations? Clin Pharmacol Ther 77 2005 451 453
78. I. Hoyo, J. Martínez-Pastor, S. Garcia-Ramiro, C. Climent, M. Brunet, and M. Cuesta et al. Decreased serum linezolid concentrations in two patients receiving linezolid and rifampicin due to bone infections Scand J Infect Dis 44 2012 548 550
79. F. Pea, P. Viale, P. Cojutti, B. Del Pin, E. Zamparini, and M. Furlanut Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients J Antimicrob Chemother 67 2012 2034 2042
80. A. Di Paolo, P. Malacarne, E. Guidotti, R. Danesi, and M. Del Tacca Pharmacological issues of linezolid: an updated critical review Clin Pharmacokinet 49 2010 439 447
81. F. Pea, M. Furlanut, P. Cojutti, F. Cristini, E. Zamparini, and L. Franceschi et al. Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis Antimicrob Agents Chemother 54 2010 4605 4610
82. D. Cattaneo, G. Orlando, V. Cozzi, L. Cordier, S. Baldelli, and S. Merli et al. Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with Gram-positive infections Int J Antimicrob Agents 41 2013 586 589
83. V.C. Wu, Y.T. Wang, C.Y. Wang, I.J. Tsai, K.D. Wu, and J.J. Hwang et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease Clin Infect Dis 42 2006 66 72
84. Y.H. Lin, V.C. Wu, I.J. Tsai, Y.L. Ho, J.J. Hwang, and Y.K. Tsau et al. High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency Int J Antimicrob Agents 28 2006 345 351
85. Y. Takahashi, Y. Takesue, K. Nakajima, K. Ichiki, Y. Wada, and T. Tsuchida et al. Implementation of a hospital-wide project for appropriate antimicrobial prophylaxis J Infect Chemother 16 2010 418 423
86. Y. Tsuji, Y. Hiraki, K. Matsumoto, A. Mizoguchi, T. Kobayashi, and S. Sadoh et al. Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction J Infect Chemother 17 2011 70 75
87. Y. Nukui, S. Hatakeyama, K. Okamoto, T. Yamamoto, A. Hisaka, and H. Suzuki et al. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia J Antimicrob Chemother 68 2013 2128 2133
88. K.M. Itani, P. Biswas, A. Reisman, H. Bhattacharyya, and A.M. Baruch Clinical efficacy of oral linezolid compared with intravenous vancomycin for the treatment of methicillin-resistant Staphylococcus aureus-complicated skin and soft tissue infections: a retrospective, propensity score-matched, case-control analysis Clin Ther 34 2012 1667 1673
89. M. Wolff, and B. Mourvillier Linezolid for the treatment of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus Clin Infect Dis 55 2012 160 161
90. F.S. Taccone, J.L. Vincent, O. Denis, and F. Jacobs Should we abandon vancomycin for treatment of methicillin-resistant Staphylococcus aureus pneumonia? Still questions to answer Clin Infect Dis 55 2012 161 163
91. K. Masuta, Y. Oba, and K. Iwata Linezolid versus vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: controversy continues Clin Infect Dis 55 2012 161
92. C. Alaniz, and J.M. Pogue Vancomycin versus linezolid in the treatment of methicillin-resistant Staphylococcus aureus nosocomial pneumonia: implications of the ZEPHyR trial Ann Pharmacother 46 2012 1432 1435
93. M.W. Pletz, O. Burkhardt, and T. Welte Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? Comparison of pharmacology and clinical efficacy Eur J Med Res 15 2010 507 513
94. I.M. Gould, J.M. Miró, and M.J. Rybak Daptomycin: the role of high-dose and combination therapy for Gram-positive infections Int J Antimicrob Agents 42 2013 202 210
95. A. Dhand, A.S. Bayer, J. Pogliano, S.J. Yang, M. Bolaris, and V. Nizet et al. Use of antistaphylococcal β-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding Clin Infect Dis 53 2011 158 163
96. P.A. Moise, M. Amodio-Groton, M. Rashid, K.C. Lamp, H.L. Hoffman-Roberts, and G. Sakoulas et al. Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant β-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment Antimicrob Agents Chemother 57 2013 1192 1200
97. K.H. Rand, and H.J. Houck Synergy of daptomycin with oxacillin and other β-lactams against methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 48 2004 2871 2875
98. S.J. Yang, Y.Q. Xiong, S. Boyle-Vavra, R. Daum, T. Jones, and A.S. Bayer Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the 'seesaw effect') Antimicrob Agents Chemother 54 2010 3161 3169
99. A.D. Berti, G. Sakoulas, V. Nizet, R. Tewhey, and W.E. Rose β-Lactam antibiotics targeting PBP1 selectively enhance daptomycin activity against methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 57 2013 5005 5012
100. A. Vena, M. Falcone, E. Comandini, M. Meledandri, A. Novelli, and F. Campanile et al. Daptomycin plus trimethoprim/sulfamethoxazole combination therapy in post-neurosurgical meningitis caused by linezolid-resistant Staphylococcus epidermidis Diagn Microbiol Infect Dis 76 2013 99 102
101. P. Di Carlo, N. D'Alessandro, G. Guadagnino, C. Bonura, C. Mammina, and M. Lunetta et al. High dose of trimethoprim-sulfamethoxazole and daptomycin as a therapeutic option for MRSA endocarditis with large vegetation complicated by embolic stroke: a case report and literature review Infez Med 21 2013 45 49
102. L.M. Avery, M.E. Steed, A.E. Woodruff, M. Hasan, and M.J. Rybak Daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazole Antimicrob Agents Chemother 56 2012 5990 5993
103. J.M. Miró, J.M. Entenza, A. Del Río, M. Velasco, X. Castañeda, and C. Garcia de la Mària et al. Hospital Clinic Experimental Endocarditis Study Group High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis Antimicrob Agents Chemother 56 2012 4511 4515
104. L.Y. Chen, C.H. Huang, S.C. Kuo, C.Y. Hsiao, M.L. Lin, and F.D. Wang et al. High-dose daptomycin and fosfomycin treatment of a patient with endocarditis caused by daptomycin-nonsusceptible Staphylococcus aureus: case report BMC Infect Dis 11 2011 152
105. C. Garrigós, O. Murillo, G. Euba, R. Verdaguer, F. Tubau, and C. Cabellos et al. Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 54 2010 5251 5256
106. J.M. Miró, C. García-de-la-Mària, Y. Armero, D. Soy, A. Moreno, and A. del Río et al. Hospital Clinic Experimental Endocarditis Study Group Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 53 2009 4172 4177
107. J. Parra-Ruiz, C. Vidaillac, W.E. Rose, and M.J. Rybak Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm Antimicrob Agents Chemother 54 2010 4329 4334
108. W.E. Rose, A.D. Berti, J.B. Hatch, and D.G. Maki Relationship of in vitro synergy and treatment outcome with daptomycin plus rifampin in patients with invasive methicillin-resistant Staphylococcus aureus infections Antimicrob Agents Chemother 57 2013 3450 3452
109. K. Jugun, P. Vaudaux, J. Garbino, L. Pagani, P. Hoffmeyer, and D. Lew et al. The safety and efficacy of high-dose daptomycin combined with rifampicin for the treatment of Gram-positive osteoarticular infections Int Orthop 37 2013 1375 1380
110. M. Lefebvre, C. Jacqueline, G. Amador, V. Le Mabecque, A. Miegeville, and G. Potel et al. Efficacy of daptomycin combined with rifampicin for the treatment of experimental methicillin-resistant Staphylococcus aureus (MRSA) acute osteomyelitis Int J Antimicrob Agents 36 2010 542 544
111. A. Mélard, L.G. Garcia, D. Das, R. Rozenberg, P.M. Tulkens, and F. Van Bambeke et al. Activity of ceftaroline against extracellular (broth) and intracellular (THP-1 monocytes) forms of methicillin-resistant Staphylococcus aureus: comparison with vancomycin, linezolid and daptomycin J Antimicrob Chemother 68 2013 648 658
112. H.S. Sader, R.K. Flamm, and R.N. Jones Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011 Antimicrob Agents Chemother 57 2013 3178 3181
113. A.A. Bhalodi, J.L. Crandon, D. Biek, and D.P. Nicolau Efficacy of ceftaroline fosamil in a staphylococcal murine pneumonia model Antimicrob Agents Chemother 56 2012 6160 6165
114. T.T. Ho, J. Cadena, L.M. Childs, M. Gonzalez-Velez, and J.S. 2nd. Lewis Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy J Antimicrob Chemother 67 2012 1267 1270
115. A.P. MacGowan, A.R. Noel, S. Tomaselli, and K.E. Bowker Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection Antimicrob Agents Chemother 57 2013 2451 2456
116. R.E. Mendes, A. Tsakris, H.S. Sader, R.N. Jones, D. Biek, and P. McGhee et al. Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline J Antimicrob Chemother 67 2012 1321 1324
117. Y. Ikeda, J. Ban, T. Ishikawa, S. Hashiguchi, S. Urayama, and H. Horibe Stability and stabilization studies of TAK-599 (ceftaroline fosamil), a novel N-phosphono type prodrug of anti-methicillin resistant Staphylococcus aureus cephalosporin T-91825 Chem Pharm Bull (Tokyo) 56 2008 1406 1411
118. A.F. Shorr, M. Kollef, P.B. Eckburg, L. Llorens, and H.D. Friedland Assessment of ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia due to Streptococcus pneumoniae: insights from two randomized trials Diagn Microbiol Infect Dis 75 2013 298 303
119. D.J. Farrell, R.K. Flamm, H.S. Sader, and R.N. Jones Spectrum and potency of ceftaroline tested against leading pathogens causing skin and soft-tissue infections in Europe (2010) Int J Antimicrob Agents 41 2013 337 342
120. R.K. Flamm, H.S. Sader, J.M. Streit, and R.N. Jones Activity of ceftobiprole tested against pathogens associated with hospital-acquired bacterial pneumonia in Europe 23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 27-30 April, Berlin, Germany 2013 [P1625]
121. A.E. Muller, A.H. Schmitt-Hoffmann, N. Punt, and J.W. Mouton Monte Carlo simulations based on phase 1 studies predict target attainment of ceftobiprole in nosocomial pneumonia patients: a validation study Antimicrob Agents Chemother 57 2013 2047 2053
122. P.R. Lagacé-Wiens, and E. Rubinstein Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia Expert Opin Drug Metab Toxicol 9 2013 789 799
123. S.C. Nicholson, T. Welte, T.M. File Jr., R.S. Strauss, B. Michiels, and P. Kaul et al. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation Int J Antimicrob Agents 39 2012 240 246
124. J.B. Locke, G.E. Zurenko, K.J. Shaw, and K. Bartizal Tedizolid for the management of human infections: in vitro characteristics Clin Infect Dis 58 Suppl. 1 2014 S35 S42